Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Mining and NextGen Sciences Plan to Produce Protein Chips

NEW YORK, Nov. 5—Molecular Mining and NextGen Sciences are collaborating to develop and produce protein biochips, Molecular Mining announced Wednesday.

In the partnership, NextGen will use Molecular Mining’s GeneLinker gene expression analysis software. The software package, launched last spring, enables data filtering and transformation, sorting and clustering, and classification and prioritization of genes along with a suite of visualization tools.

NextGen, based in Huntingdon, Cambridgeshire, UK, was founded in 2000 to develop technologies for genomic and proteomic research. It is now developing a novel technique of attaching proteins to biochip surfaces, and also working on developing new substances for use in the biochip surfaces themselves

“When you are working with protein biochips, there is a lot of information associated with the proteins and the analysis,” said company business development director Linda Cammish. “That sort of data processing really isn’t our core technology, and nor do we wish it to be. Therefore our process has been to form a number of partnerships, including the one with MMC, since their strength is in the use of high performance analysis software.”

The collaboration will help Molecular Mining evaluate future need for protein biochip data, said the company in a statement.

There are no explicit financial agreements to the research partnership, a company official said.
The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.